Lundbeck executive remains confident about Alzheimer's drug after new analysis
Even though Rexulti did not deliver quick results in phase III against Alzheimer's disease, Lundbeck's Head of R&D Johan Luthman still sees plenty of potential in the trial which is now set to be concluded in the new year.
BY ELIZABETH MØNSTED JOHANSEN & ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN
Danish pharmaceutical company Lundbeck had hoped for quick, efficient results in the third clinical trial with Rexulti as a treatment for agitation in Alzheimer's patients, but this hope was soon extinguished.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck carries on Rexulti study after new analysis
For subscribers
Lundbeck drug hope moves closer to moment of truth
For subscribers
